紫杉醇-卡铂联合或不联合尼达尼布一线治疗复发或晚期宫颈癌的随机II期BGOG/ENGOT-cx1研究
这项双盲随机II期研究纳入120例一线复发或原发晚期(FIGO IVB期)宫颈癌患者,比较紫杉醇-卡铂联合口服尼达尼布200 mg每日两次与安慰剂的疗效。主要终点1.5年无进展生存率尼达尼布组为15.1%、对照组为12.8%(p=0.057),研究达到主要终点;尼达尼布组中位总生存期21.7个月,对照组16.4个月。
要点
- 尼达尼布组1.5年无进展生存率15.1%,对照组12.8%(p=0.057),研究达到主要终点。
- 尼达尼布组中位总生存期21.7个月,对照组16.4个月。
- 尼达尼布组确认的RECIST缓解率48%,对照组39%;尼达尼布未出现新的不良事件,但贫血和发热性中性粒细胞减少的严重不良事件数量在数值上更多。
核心结论
- 研究达到主要终点,尼达尼布组无进展生存期延长。
- 未观察到新的安全性信号。
研究设计与样本
- 双盲II期随机研究,纳入一线复发或原发晚期(FIGO IVB期)宫颈癌患者。
- 患者接受卡铂-紫杉醇联合口服尼达尼布200 mg每日两次或安慰剂。
- 共随机120例患者(尼达尼布组62例,对照组58例),中位随访35个月。
- 主要终点为1.5年无进展生存率,α=0.15,β=80%,单侧检验。
主要发现
- 总人群基线特征:鳞状细胞癌62%,既往放疗64%,原发晚期25%,复发75%。
- 1.5年无进展生存率尼达尼布组15.1% vs 对照组12.8%(p=0.057),利于尼达尼布组。
- 中位总生存期尼达尼布组21.7个月 vs 对照组16.4个月。
- 确认的RECIST缓解率尼达尼布组48% vs 对照组39%。
- 尼达尼布未出现新的不良事件,但贫血和发热性中性粒细胞减少的严重不良事件数量在数值上更多;研究期间及结束时两组全球健康状况相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor. The aim was to establish the role of nintedanib in addition to paclitaxel and carboplatin in first-line recurrent/metastatic cervical cancer. METHODS: Double-blind phase II randomized study in patients with first-line recurrent or primary advanced (FIGO stage IVB) cervical cancer. Patients received carboplatin-paclitaxel with oral nintedanib 200 mg BID/placebo. The primary endpoint was progression-free survival (PFS) at 1.5 years and α = 0.15, β = 80%, one sided. RESULTS: 120 patients (62 N, 58C) were randomized. Median follow-up was 35 months. Baseline characteristics were similar in both groups (total population: squamous cell carcinoma 62%, prior radiotherapy 64%, primary advanced 25%, recurrent 75%). The primary endpoint was met with a PFS at 1.5 years of 15.1% versus 12.8% in favor of the nintedanib arm (p = 0.057). Median overall survival (OS) was 21.7 and 16.4 months for N and C, respectively. Confirmed RECIST response rate was 48% for N and 39% for C. No new adverse events were noted for N. However, N was associated with numerically more serious adverse events for anemia and febrile neutropenia. Global health status during and at the end of the study was similar in both arms. CONCLUSION: The study met its primary endpoint with a prolonged PFS in the N arm. No new safety signals were observed.
引用
- Vergote I, Van Nieuwenhuysen E, Casado A, et al. Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Gynecol Oncol. 2023. PMID: 37167896. doi:10.1016/j.ygyno.2023.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。